SG10201505075TA - Simultaneous, Integrated Selection And Evolution Of Antibody/Protein Performance And Expression In Production Hosts - Google Patents
Simultaneous, Integrated Selection And Evolution Of Antibody/Protein Performance And Expression In Production HostsInfo
- Publication number
- SG10201505075TA SG10201505075TA SG10201505075TA SG10201505075TA SG10201505075TA SG 10201505075T A SG10201505075T A SG 10201505075TA SG 10201505075T A SG10201505075T A SG 10201505075TA SG 10201505075T A SG10201505075T A SG 10201505075TA SG 10201505075T A SG10201505075T A SG 10201505075TA
- Authority
- SG
- Singapore
- Prior art keywords
- evolution
- antibody
- simultaneous
- expression
- production hosts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Computational Biology (AREA)
- Ecology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27116809P | 2009-07-17 | 2009-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201505075TA true SG10201505075TA (en) | 2015-07-30 |
Family
ID=43450243
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201505075TA SG10201505075TA (en) | 2009-07-17 | 2010-07-16 | Simultaneous, Integrated Selection And Evolution Of Antibody/Protein Performance And Expression In Production Hosts |
| SG10201700096VA SG10201700096VA (en) | 2009-07-17 | 2010-07-16 | Simultaneous, Integrated Selection And Evolution Of Antibody/Protein Performance And Expression In Production Hosts |
| SG2012003356A SG177687A1 (en) | 2009-07-17 | 2010-07-16 | Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201700096VA SG10201700096VA (en) | 2009-07-17 | 2010-07-16 | Simultaneous, Integrated Selection And Evolution Of Antibody/Protein Performance And Expression In Production Hosts |
| SG2012003356A SG177687A1 (en) | 2009-07-17 | 2010-07-16 | Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US8859467B2 (en) |
| EP (6) | EP3042957B1 (en) |
| JP (3) | JP6193570B2 (en) |
| KR (5) | KR20180010347A (en) |
| CN (2) | CN107090031A (en) |
| AU (5) | AU2010273974B2 (en) |
| BR (2) | BR112012001171B1 (en) |
| CA (2) | CA2768247C (en) |
| DK (5) | DK3406717T3 (en) |
| ES (3) | ES2701931T3 (en) |
| HK (1) | HK1210623A1 (en) |
| HU (1) | HUE029328T2 (en) |
| IN (1) | IN2012DN00737A (en) |
| MX (2) | MX347654B (en) |
| MY (2) | MY160472A (en) |
| PL (2) | PL3042957T3 (en) |
| PT (1) | PT3042957T (en) |
| SG (3) | SG10201505075TA (en) |
| WO (1) | WO2011009058A2 (en) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3406717T3 (en) | 2009-07-17 | 2020-03-16 | Bioatla Llc | AT THE SAME TIME, INTEGRATED SELECTION AND DEVELOPMENT OF ANTIBODY / PROTEIN PERFORMANCE AND EXPRESSION OF PRODUCT HOUSES |
| WO2011109726A2 (en) * | 2010-03-05 | 2011-09-09 | Bioatla Llc | Homologous multi-specific antibodies |
| WO2012009026A2 (en) | 2010-07-16 | 2012-01-19 | Bioatla Llc | Novel methods of protein evolution |
| AU2015242961B2 (en) * | 2010-07-16 | 2017-03-02 | Bioatla, Llc | Novel methods of protein evolution |
| KR20130096731A (en) | 2010-09-08 | 2013-08-30 | 할로자임, 아이엔씨 | Methods for assessing and identifying or evolving conditionally active therapeutic proteins |
| EP2773964A4 (en) * | 2011-11-03 | 2015-06-24 | Stc Biolog Inc | Method for determination of pharmacological properties of recombinant proteins |
| US20140323315A1 (en) * | 2013-04-29 | 2014-10-30 | Adimab, Llc | Polyspecificity reagents, methods for their preparation and use |
| EP3447493B1 (en) * | 2014-01-07 | 2020-05-13 | Bioatla, LLC | Proteins targeting orthologs |
| GB201407852D0 (en) | 2014-05-02 | 2014-06-18 | Iontas Ltd | Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules |
| CN106459960A (en) * | 2014-05-13 | 2017-02-22 | 生物蛋白有限公司 | Conditionally active biological proteins |
| WO2016004242A1 (en) * | 2014-07-01 | 2016-01-07 | Stc Biologics, Inc. | A method for development of recombinant proteins with fingerprint like similarity to the reference product |
| EP4074735A1 (en) | 2014-08-28 | 2022-10-19 | BioAtla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
| CA2959786A1 (en) | 2014-09-03 | 2016-03-10 | Bioatla, Llc | Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts |
| CA3225013A1 (en) | 2015-02-24 | 2016-09-01 | Bioatla, Llc | Conditionally active proteins |
| WO2017053807A2 (en) * | 2015-09-23 | 2017-03-30 | Genentech, Inc. | Optimized variants of anti-vegf antibodies |
| CN115521374A (en) | 2015-11-02 | 2022-12-27 | 生物蛋白有限公司 | Conditionally active polypeptides |
| JP7051715B2 (en) | 2016-05-13 | 2022-04-11 | バイオアトラ、エルエルシー | Anti-Ror2 antibodies, antibody fragments, their immune conjugates and their use |
| SG10201913144TA (en) | 2017-07-11 | 2020-03-30 | Compass Therapeutics Llc | Agonist antibodies that bind human cd137 and uses thereof |
| WO2019089753A2 (en) | 2017-10-31 | 2019-05-09 | Compass Therapeutics Llc | Cd137 antibodies and pd-1 antagonists and uses thereof |
| EP3713961A2 (en) | 2017-11-20 | 2020-09-30 | Compass Therapeutics LLC | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| MX2021005594A (en) | 2018-11-13 | 2021-10-22 | Compass Therapeutics Llc | Multispecific binding constructs against checkpoint molecules and uses thereof. |
| EP3966227A1 (en) | 2019-05-07 | 2022-03-16 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| CN111048154B (en) * | 2019-12-10 | 2023-06-06 | 上海药明生物技术有限公司 | Method for mapping antibody epitope |
| CN111462815B (en) * | 2020-03-27 | 2023-05-02 | 上海祥耀生物科技有限责任公司 | Construction method and device of antibody library |
| US11506060B1 (en) * | 2021-07-15 | 2022-11-22 | Honeywell International Inc. | Radial turbine rotor for gas turbine engine |
| WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2023220695A2 (en) | 2022-05-13 | 2023-11-16 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| WO2024030976A2 (en) | 2022-08-03 | 2024-02-08 | Voyager Therapeutics, Inc. | Compositions and methods for crossing the blood brain barrier |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (en) | 1970-11-10 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4957858A (en) | 1986-04-16 | 1990-09-18 | The Salk Instute For Biological Studies | Replicative RNA reporter systems |
| US4883750A (en) | 1984-12-13 | 1989-11-28 | Applied Biosystems, Inc. | Detection of specific sequences in nucleic acids |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| AU622104B2 (en) | 1987-03-11 | 1992-04-02 | Sangtec Molecular Diagnostics Ab | Method of assaying of nucleic acids, a reagent combination and kit therefore |
| CA1323293C (en) | 1987-12-11 | 1993-10-19 | Keith C. Backman | Assay using template-dependent nucleic acid probe reorganization |
| DE68908054T2 (en) | 1988-01-21 | 1994-03-10 | Genentech Inc | REINFORCEMENT AND DETECTION OF NUCLEIC ACID SEQUENCES. |
| CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
| EP0365627B1 (en) | 1988-03-24 | 1993-12-22 | University Of Iowa Research Foundation | Catalytic hybridization systems for the detection of nucleic acid sequences based on their activity as cofactors in catalytic reactions in which a complementary labeled nucleic acid probe is cleaved |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| JPH08503706A (en) | 1992-11-24 | 1996-04-23 | ジー．ディー．サール アンド カンパニー | Interleukin-3 (IL-3) multiple mutant polypeptide |
| US6171820B1 (en) | 1995-12-07 | 2001-01-09 | Diversa Corporation | Saturation mutagenesis in directed evolution |
| US6562594B1 (en) | 1999-09-29 | 2003-05-13 | Diversa Corporation | Saturation mutagenesis in directed evolution |
| US20030219752A1 (en) * | 1995-12-07 | 2003-11-27 | Diversa Corporation | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof |
| US6238884B1 (en) | 1995-12-07 | 2001-05-29 | Diversa Corporation | End selection in directed evolution |
| US6764835B2 (en) | 1995-12-07 | 2004-07-20 | Diversa Corporation | Saturation mutageneis in directed evolution |
| US8137906B2 (en) * | 1999-06-07 | 2012-03-20 | Sloning Biotechnology Gmbh | Method for the synthesis of DNA fragments |
| US7033781B1 (en) | 1999-09-29 | 2006-04-25 | Diversa Corporation | Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating |
| US7163681B2 (en) * | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
| US7189830B2 (en) | 2001-02-19 | 2007-03-13 | Merck Patent Gmbh | Anti-KSA/IL-2 fusion proteins with reduced immunogenicity |
| US7117096B2 (en) | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
| EP1421203A4 (en) * | 2001-05-17 | 2005-06-01 | Diversa Corp | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof |
| US7647184B2 (en) * | 2001-08-27 | 2010-01-12 | Hanall Pharmaceuticals, Co. Ltd | High throughput directed evolution by rational mutagenesis |
| KR20060034650A (en) * | 2003-06-27 | 2006-04-24 | 바이오렌 인코포레이티드 | Look-through mutagenesis |
| GB0520169D0 (en) * | 2005-10-04 | 2005-11-09 | Celltech R&D Ltd | Biological products |
| AU2006304387A1 (en) * | 2005-10-14 | 2007-04-26 | Medimmune, Llc | Cell display of antibody libraries |
| EP2617827A1 (en) * | 2007-03-26 | 2013-07-24 | Celexion, LLC | Method for displaying engineered proteins on a cell surface |
| WO2009059235A2 (en) | 2007-11-01 | 2009-05-07 | Facet Biotech Corporation | Immunoglobulin display vectors |
| KR20100091997A (en) | 2007-11-02 | 2010-08-19 | 더 스크립스 리서치 인스티튜트 | Directed evolution using proteins comprising unnatural amino acids |
| US8312249B1 (en) | 2008-10-10 | 2012-11-13 | Apple Inc. | Dynamic trampoline and structured code generation in a signed code environment |
| DK3406717T3 (en) | 2009-07-17 | 2020-03-16 | Bioatla Llc | AT THE SAME TIME, INTEGRATED SELECTION AND DEVELOPMENT OF ANTIBODY / PROTEIN PERFORMANCE AND EXPRESSION OF PRODUCT HOUSES |
| FR2957821B1 (en) | 2010-03-24 | 2014-08-29 | Inst Francais Du Petrole | NEW AREA OF CATALYST REGENERATION DIVIDED IN SECTORS FOR REGENERATIVE CATALYTIC UNITS |
-
2010
- 2010-07-16 DK DK18183032.4T patent/DK3406717T3/en active
- 2010-07-16 CN CN201611220313.3A patent/CN107090031A/en active Pending
- 2010-07-16 EP EP16157965.1A patent/EP3042957B1/en active Active
- 2010-07-16 CN CN2010800388394A patent/CN102625848A/en active Pending
- 2010-07-16 BR BR112012001171-5A patent/BR112012001171B1/en active IP Right Grant
- 2010-07-16 EP EP18183032.4A patent/EP3406717B1/en active Active
- 2010-07-16 SG SG10201505075TA patent/SG10201505075TA/en unknown
- 2010-07-16 MX MX2015005873A patent/MX347654B/en unknown
- 2010-07-16 PL PL16157965T patent/PL3042957T3/en unknown
- 2010-07-16 KR KR1020187002028A patent/KR20180010347A/en active Application Filing
- 2010-07-16 DK DK16157965.1T patent/DK3042957T3/en active
- 2010-07-16 MX MX2012000803A patent/MX2012000803A/en active IP Right Grant
- 2010-07-16 EP EP10800618.0A patent/EP2454376B1/en active Active
- 2010-07-16 BR BR122015012748-3A patent/BR122015012748A2/en not_active Application Discontinuation
- 2010-07-16 EP EP15156820.1A patent/EP2907873B1/en active Active
- 2010-07-16 DK DK15156820.1T patent/DK2907873T3/en active
- 2010-07-16 JP JP2012520813A patent/JP6193570B2/en active Active
- 2010-07-16 HU HUE15156820A patent/HUE029328T2/en unknown
- 2010-07-16 WO PCT/US2010/042302 patent/WO2011009058A2/en active Application Filing
- 2010-07-16 DK DK19210622.7T patent/DK3636759T3/en active
- 2010-07-16 KR KR1020217042385A patent/KR20220002712A/en not_active Application Discontinuation
- 2010-07-16 SG SG10201700096VA patent/SG10201700096VA/en unknown
- 2010-07-16 KR KR1020217002264A patent/KR20210013294A/en not_active Application Discontinuation
- 2010-07-16 MY MYPI2012000207A patent/MY160472A/en unknown
- 2010-07-16 ES ES16196481T patent/ES2701931T3/en active Active
- 2010-07-16 EP EP19210622.7A patent/EP3636759B1/en active Active
- 2010-07-16 KR KR1020127003948A patent/KR101823872B1/en active IP Right Grant
- 2010-07-16 ES ES15156820.1T patent/ES2581318T3/en active Active
- 2010-07-16 PL PL15156820.1T patent/PL2907873T3/en unknown
- 2010-07-16 KR KR1020197004078A patent/KR20190017070A/en not_active IP Right Cessation
- 2010-07-16 ES ES16157965.1T patent/ES2652340T3/en active Active
- 2010-07-16 PT PT161579651T patent/PT3042957T/en unknown
- 2010-07-16 CA CA2768247A patent/CA2768247C/en active Active
- 2010-07-16 EP EP16196481.2A patent/EP3156485B1/en active Active
- 2010-07-16 MY MYPI2015002586A patent/MY173037A/en unknown
- 2010-07-16 DK DK16196481.2T patent/DK3156485T3/en active
- 2010-07-16 SG SG2012003356A patent/SG177687A1/en unknown
- 2010-07-16 AU AU2010273974A patent/AU2010273974B2/en active Active
- 2010-07-16 US US13/384,362 patent/US8859467B2/en active Active
- 2010-07-16 CA CA3034484A patent/CA3034484A1/en active Pending
-
2011
- 2011-11-17 US US13/298,559 patent/US10106788B2/en active Active
-
2012
- 2012-01-25 IN IN737DEN2012 patent/IN2012DN00737A/en unknown
-
2014
- 2014-09-09 US US14/481,564 patent/US10047357B2/en active Active
-
2015
- 2015-05-06 JP JP2015094521A patent/JP6193913B2/en active Active
- 2015-09-15 HK HK15109001.1A patent/HK1210623A1/en unknown
- 2015-10-16 AU AU2015243076A patent/AU2015243076B2/en active Active
-
2017
- 2017-05-15 AU AU2017203243A patent/AU2017203243B2/en active Active
- 2017-06-02 JP JP2017109593A patent/JP6681131B2/en active Active
-
2018
- 2018-08-31 US US16/118,673 patent/US10920216B2/en active Active
-
2019
- 2019-05-31 AU AU2019203813A patent/AU2019203813B2/en active Active
-
2021
- 2021-01-27 US US17/159,936 patent/US11976381B2/en active Active
- 2021-05-19 AU AU2021203220A patent/AU2021203220B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201700096VA (en) | Simultaneous, Integrated Selection And Evolution Of Antibody/Protein Performance And Expression In Production Hosts | |
| IL250624A0 (en) | Anti-fgfr3 antibodies and methods using same | |
| EP3460064B8 (en) | Efficient protein expression in vivo using modified rna (mod-rna) | |
| GB0922434D0 (en) | antibodies and fragments thereof | |
| EP2433968A4 (en) | Dual targeting antibody of novel form, and use thereof | |
| IL218753A0 (en) | Protein arrays and uses thereof | |
| ZA201107486B (en) | Anti-tnf-x antibodies and their uses | |
| EP2494062A4 (en) | Anti-glp-1r antibodies and their uses | |
| EP2525813A4 (en) | Anti-ilt5 antibodies and ilt5-binding antibody fragments | |
| PT3043182T (en) | Monoclonal antibodies to hemoglobin variants c, s, e and d | |
| IL236237A (en) | Tmem154 antibodies and fragments and uses thereof | |
| HK1162538A1 (en) | Novel anti-51 antibodies and uses thereof -51 | |
| IL220536A0 (en) | Anti - bv8 antibodies and uses thereof | |
| IL219136A0 (en) | Anti-hepsin antibodies and methods using same | |
| ZA201100019B (en) | Variant hhip1 protein and methods and uses thereof | |
| GB0903151D0 (en) | Antibody uses and methods | |
| IL214527A0 (en) | Anti-mst1r antibodies and uses thereof | |
| EP2540742A4 (en) | Anti-cyr61 protein monoclonal antibodies and uses thereof | |
| TH136549B (en) | Protein drink And methods of preparation of this drink | |
| AU2009904099A0 (en) | Antibodies to C5L2 and C5aR | |
| GB0902222D0 (en) | Protein expression | |
| GB0909384D0 (en) | Protein |